Compare GoPro Inc (GPRO) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? GoPro Inc trades at $1.19 (market cap $253.82M), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 229.1× GoPro Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while GoPro Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| GPRO | TAK | |
|---|---|---|
Market Cap | $253.82M | $58.16B |
Volume | 9,909,466 | 2,467,530 |
Sector | Technology | Health |
52-Week High | $2.35 | $19.05 |
52-Week Low | $0.58 | $13.23 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $312.60M | $86.04B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.22, down 7.58% on the day, amid volatile trading following a recent surge driven by merger news and influencer investment. The stock shows bullish technical signals with oversold RSI conditions, but fundamentals remain weak with declining revenues and persistent net losses. Recent developments include a proposed $285 million merger with Starman Optical and significant stake acquisition by YouTube creator Markiplier, creating both opportunity and uncertainty for shareholders.
The outlook remains highly speculative with the merger offering potential upside but facing shareholder litigation over valuation concerns. Key risks include continued operational losses, competitive pressures from smartphones, and merger execution challenges. Analyst sentiment is mixed with only 21% buy ratings, reflecting skepticism about the company's standalone prospects versus merger-driven speculation.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
